Talzenna bags EU approval for gBRCA-mutated breast cancer
An important milestone in breast cancer treatment has been reached as the European Commission announced the approval of Pfizer’s Talzenna for patients with inherited BRCA-mutated locally advanced or metastatic breast cancer. To learn more about this important approval, click the link below: http://www.pharmatimes.com/news/talzenna_bags_eu_approval_for_gbrca-mutated_breast_cancer_1292259?fbclid=IwAR0vDYAm_zBuOopYI69k2izCEkeU_kHgKbqTKroxOmAG5pmf2l9RZTujRE4
